Rubella Vaccine Safety: Immunocompromised Patients and Pregnancy

The rubella vaccine contains a live attenuated virus. Because it can replicate in the body, it is contraindicated in certain groups:

Who Should Not Receive the Live Rubella Vaccine

• Immunocompromised individuals: Those with primary immunodeficiency, HIV with low CD4 counts, leukemia, lymphoma, or on high-dose immunosuppressive therapy (e.g., chemotherapy, biologics, prolonged steroids). The vaccine virus could cause disease.
• Pregnant women: Theoretical risk to the fetus. Women should avoid pregnancy for at least 4 weeks after vaccination.

Exposure During Pregnancy

If a pregnant woman is exposed to rubella, she should not receive the vaccine. Instead, she should contact her healthcare provider immediately. Depending on gestational age and immunity status, intramuscular immune globulin (IG) may be offered to reduce—though not eliminate—the risk of congenital rubella syndrome. The vaccine is given postpartum if she is not immune.

Key Points

• Rubella vaccine is typically given as MMR (measles, mumps, rubella).
• Screening for rubella immunity is standard in prenatal care.
• Household contacts of immunocompromised persons should be vaccinated to create a protective "cocoon."

Always consult a healthcare provider for personalized advice regarding vaccination and exposure management.